Canada markets closed

Insmed Incorporated (INSM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
76.71-0.32 (-0.42%)
At close: 04:00PM EDT
76.97 +0.26 (+0.33%)
After hours: 07:05PM EDT

Insmed Incorporated

700 US Highway 202/206
Bridgewater, NJ 08807
United States
908 977 9900
https://www.insmed.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees912

Key Executives

NameTitlePayExercisedYear Born
Mr. William H. Lewis J.D., M.B.A.President, CEO & Chairman1.59M1.11M1969
Ms. Sara M. Bonstein M.B.A.Chief Financial Officer810.4kN/A1981
Mr. Roger Adsett M.B.A.Chief Operating Officer1.01MN/A1969
Mr. John Drayton Wise M.B.A.Chief Commercial Officer888.85kN/A1975
Dr. Martina Flammer M.B.A., M.D.Chief Medical Officer872.29k179.49k1964
Mr. Brian K. Kaspar Ph.D.Chief Scientific OfficerN/AN/A1974
Eleanor BarisserAssociate Director of Investor RelationsN/AN/AN/A
Mr. Michael Alexander Smith J.D.Chief Legal Officer & Corporate SecretaryN/AN/A1978
Mandy FaheyExecutive Director of Corporate CommunicationsN/AN/AN/A
Ms. S. Nicole Schaeffer M.B.A.Chief People Strategy Officer660.81k1.18M1968
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Corporate Governance

Insmed Incorporated’s ISS Governance QualityScore as of July 1, 2024 is 7. The pillar scores are Audit: 6; Board: 4; Shareholder Rights: 9; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.